Journal of AIDS & Clinical Research

Background: Adolescents and youths have an increased probability for risky sexual behaviors because of their developmental stage. Besides, they are risk taker who are more likely to make decision about without adequately considering the consequence.

Objectives: To assess the risky sexual behaviour among TVET college students of Mizan-Aman town, South west Ethiopia, 2018.

Methods: An institutional based descriptive cross-sectional study was conducted among systematically selected 453 college students at Mizan-Aman TVET college, Ethiopia, April 2018. Data was collected using structured selfadministered questionnaire. The data was entered using EPI-DATA version 4.2.0.0, cleaned and analyzed using SPSS version 20 statistical software for windows. Results was presented using tables, graphs and numerical summery measures like mean and standard deviation (SD).

Results: Of 453 participants who filled the questionnaire, 54.7% (248) were males and 46.4% (210) were females. The mean age of the respondents was 19.95 (± 2 SD) years ranges from 18 to 30 years. Of 453 participants, 39.7% (180) of them were sexually active. The mean age of sexual intercourse was 17.64 (± 2 SD) years. Nearly three-fourth, 73.4% (132) of student’s reason of having sexual intercourse for the first time was falling in love. Out of sexually active students 17.8% (32) of the students have low risky sexual behaviour while 69.4% (125) and 12.8% (23) of them have average risk and high risky sexual behaviour respectively. More than half, 62.2% (112) of the respondents were used condom for their first sexual intercourse and 45.6% (82) were had multiple sexual partners.

Conclusion: This finding shows the public health importance of risky sexual behavior among college students in Ethiopia. So, equipping adolescents with sexual and reproductive health is paramount important to protect them from risky sexual behavior.

Atazanavir is a protease inhibitor that is used as an antiretroviral drug. It is co-formulated with ritonavir to boost its plasma concentration and given together with two other antiretrovirals for a highly active regimen. As much as the drug literature warns of a cutaneous reaction, it has not communicated effectively on the possibility pf this occurring in patients with a sulphur allergy. No such case has been reported before. We report a case of a cutaneous adverse drug reaction in a male patient with a known allergy to sulphur in whom it was used for post-exposure prophylaxis. There is need for taking comprehensive patient history and relate it to reactions reported in literature to prevent recurrence of adverse reactions.